Abstract
Until recently, the signaling events elicited in vascular smooth muscle cells by angiotensin II (Ang II) were considered to be rapid, short-lived, and divided into separate linear pathways, where intracellular targets of the phospholipase C-diacylglycerol-Ca2+ axis were distinct from those of the tyrosine kinase- and mitogen-activated protein kinase- dependent pathways. However, these major intracellular signaling cascades do not function independently and are actively engaged in cross-talk. Downstream signals from the Ang II-bound receptors converge to elicit complex and multiple responses. The exact adapter proteins or “go-between” molecules that link the multiple intracellular pathways await clarification. Ang II induces a multitude of actions in various tissues, and the signaling events following occupancy and activation of angiotensin receptors are tightly controlled and extremely complex. Alterations of these highly regulated signaling pathways in vascular smooth cells may be pivotal in structural and functional abnormalities that underlie vascular pathological processes in cardiovascular diseases such as hypertension, atherosclerosis, and post-interventional restenosis.
Footnotes
-
↵1 Address for correspondence: R. M. Touyz, M.D., Ph.D., Clinical Research Institute of Montreal, 110 Pine Ave. West, Montreal, Quebec H2W 1R7 Canada. E-mail: touyzr{at}ircm.qc.ca
-
c-Jun N-terminal kinase; PKB, protein kinase B; SAPK, stress-activated protein kinase; MKP, MAP kinase phosphatase; PHAS-I, phosphorylated heat- and acid-stable protein; eIF, eukaryotic initiation factor; PKA, protein kinase A; PG, prostaglandin; TXA, thromboxane; HPETE, hydroperoxyeicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; CRE, cAMP/calcium response element; SRE, seum response element; SIE, sis-inducing factor element ; TGF-β, transforming growth factor-β; IGF-1, insulin-like growth factor-1; bFGF, basic fibroblast growth factor; PAF, platelet-activating factor; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemoattractant protein-1; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto; MEK, MAPK/ERK kinase.
- The American Society for Pharmacology and Experimental Therapeutics
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|